132 related articles for article (PubMed ID: 27109446)
1. Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance.
Russo A; Franchina T; Ricciardi GR; Ferraro G; Scimone A; Bronte G; Russo A; Rolfo C; Adamo V
Expert Rev Anticancer Ther; 2016 Jun; 16(6):615-23. PubMed ID: 27109446
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients.
Gil M; Knetki-Wróblewska M; Niziński P; Strzemski M; Krawczyk P
Ann Med; 2023 Dec; 55(1):1018-1028. PubMed ID: 36896848
[TBL] [Abstract][Full Text] [Related]
3. Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC.
Jennings EM; Camidge DR; Gadgeel S; Barker S
Clin Lung Cancer; 2024 Mar; 25(2):91-99. PubMed ID: 38135566
[TBL] [Abstract][Full Text] [Related]
4. Emerging treatment for ALK-positive lung cancer.
Sharma J; Pareek V; Liu H; Cheng H
Expert Opin Emerg Drugs; 2016 Jun; 21(2):147-55. PubMed ID: 27122312
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.
Hong S; Chen N; Fang W; Zhan J; Liu Q; Kang S; He X; Liu L; Zhou T; Huang J; Chen Y; Qin T; Zhang Y; Ma Y; Yang Y; Zhao Y; Huang Y; Zhang L
Oncoimmunology; 2016 Mar; 5(3):e1094598. PubMed ID: 27141355
[TBL] [Abstract][Full Text] [Related]
6. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib Resensitization by Compound Mutation.
Bordi P; Del Re M; Tiseo M
N Engl J Med; 2016 May; 374(18):1790. PubMed ID: 27144863
[No Abstract] [Full Text] [Related]
8. Crizotinib Resensitization by Compound Mutation.
Shaw AT; Engelman JA
N Engl J Med; 2016 May; 374(18):1790-1. PubMed ID: 27144862
[No Abstract] [Full Text] [Related]
9. Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition.
Kerner GS; Koole MJ; Bongaerts AH; Pruim J; Groen HJ;
PLoS One; 2016; 11(5):e0149955. PubMed ID: 27137772
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
Lin YT; Yu CJ; Yang JC; Shih JY
Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.
Feng C; Liu X; Li X; Guo F; Huang C; Qin Q; Wang Y
Oncol Rep; 2016 Jun; 35(6):3460-70. PubMed ID: 27109760
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.
Hurry M; Zhou ZY; Zhang J; Zhang C; Fan L; Rebeira M; Xie J
J Med Econ; 2016 Oct; 19(10):936-44. PubMed ID: 27149298
[TBL] [Abstract][Full Text] [Related]
13. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
Ou SH; Weitz M; Jalas JR; Kelly DF; Wong V; Azada MC; Quines O; Klempner SJ
Lung Cancer; 2016 Jun; 96():15-8. PubMed ID: 27133743
[TBL] [Abstract][Full Text] [Related]
14. Response to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma translocation: A case report.
Wang W; Song Z; Zhang Y
Thorac Cancer; 2016 Apr; 7(3):355-7. PubMed ID: 27148422
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
[TBL] [Abstract][Full Text] [Related]
16. EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3.
Koh J; Jang JY; Keam B; Kim S; Kim MY; Go H; Kim TM; Kim DW; Kim CW; Jeon YK; Chung DH
Oncoimmunology; 2016 Mar; 5(3):e1108514. PubMed ID: 27141364
[TBL] [Abstract][Full Text] [Related]
17. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH
Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209
[TBL] [Abstract][Full Text] [Related]
18. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I
Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347
[TBL] [Abstract][Full Text] [Related]
19. A heterochronic genetic change from an EGFR mutation to an ALK rearrangement in a patient with lung adenocarcinoma: a case report.
Shiroyama T; Tamiya M; Hayama M; Nishihara T; Nishida T; Tanaka A; Morishita N; Suzuki H; Okamoto N; Kawahara K; Hirashima T
J Thorac Dis; 2016 May; 8(5):E345-8. PubMed ID: 27162697
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
